Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

Villiers, Pierre de; Steele, A. Duncan; Hiemstra, LA; Rappaport, Ruth; Dunning, Andrew J.; Gruber, William C.; Forrest, Bruce D.

doi:10.1016/j.vaccine.2009.09.092

Cited by 84 publications

(57 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 21 studies in the elderly that were reviewed comprised four randomized and two non‐randomized controlled trials, seven cohort studies, four case–controls and four ecological studies. Seasonal influenza vaccination provided 43–58% protection in the elderly 18, 42, 43. The seven studies in healthy adults comprised one randomized controlled trial, and three cohorts and case–control studies each.…”

Section: Resultsmentioning

confidence: 99%

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Hirve

Lambach

Paget

et al. 2016

Influenza Resp Viruses

View full text Add to dashboard Cite

AimThe evidence needed for tropical countries to take informed decisions on influenza vaccination is scarce. This article reviews policy, availability, use and effectiveness of seasonal influenza vaccine in tropical and subtropical countries.MethodGlobal health databases were searched in three thematic areas – policy, availability and protective benefits in the context of human seasonal influenza vaccine in the tropics and subtropics. We excluded studies on monovalent pandemic influenza vaccine, vaccine safety, immunogenicity and uptake, and disease burden.ResultsSeventy‐four countries in the tropics and subtropics representing 60% of the world's population did not have a national vaccination policy against seasonal influenza. Thirty‐eight countries used the Northern Hemisphere and 21 countries the Southern Hemisphere formulation. Forty‐six countries targeted children and 57 targeted the elderly; though, the age cut‐offs varied. Influenza vaccine supply increased twofold in recent years. However, coverage remained lower than five per 1000 population. Vaccine protection against laboratory‐confirmed influenza in the tropics ranged from 0% to 42% in the elderly, 20–77% in children and 50–59% in healthy adults. Vaccinating pregnant women against seasonal influenza prevented laboratory‐confirmed influenza in both mothers (50%) and their infants <6 months (49–63%).ConclusionGuidelines on vaccine composition, priority risk groups and vaccine availability varied widely. The evidence on vaccine protection was scarce. Countries in the tropics and subtropics need to strengthen and expand their evidence‐base required for making informed decisions on influenza vaccine introduction and expansion, and how much benefit to expect.

show abstract

Section: Resultsmentioning

confidence: 99%

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Hirve

Lambach

Paget

et al. 2016

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…[225] In South Africa, a randomized placebo-controlled trial in 2001 estimated LAIV efficacy against vaccine-matched influenza viruses to be 42.3%, with highest efficacy against influenza A(H3N2) viruses (52.5%), no efficacy against influenza B viruses, and no increase of severe adverse events for LAIV recipients compared to placebo. [226] A superiority trial in South Africa in 2002 found no significant difference in relative efficacy between LAIV and TIV, although this was due in part to the small number of laboratory-confirmed infections in the two study arms. [227] Finally, a study among Russian adults aged 60 and over who received either TIV or LAIV alone or a combination of the two, found a similar efficacy when TIV or LAIV was administered alone, at 50% and 51% respectively.…”

Section: Vaccine Performancementioning

confidence: 99%

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Rondy¹,

Launay

Puig-Barberà

et al. 2015

Eurosurveillance

View full text Add to dashboard Cite

show abstract

“…Other trials have reported a low incidence of adverse effects (0%-3%) and no significant difference in serious adverse events between influenza vaccine and placebo. [15][16][17] Of the RCTs, FLUCAD 31 was likely the most well designed. The authors attempted to minimize bias and confounding through appropriate randomization, use of intention-to-treat analyses, and minimal loss to follow-up.…”

Section: Discussionmentioning

confidence: 99%

“…14 However, in prospective randomized trials that included CV outcomes for safety assessment, influenza vaccination was not associated with a reduction in CV events, [15][16][17][18] although these trials were limited by low event rates and potential for misclassification. 19 Both the American Heart Association/American College of Cardiology and the European Society of Cardiology recommend the influenza vaccine annually for individuals with established CVD [20][21][22] without specifically stating that the purpose is to reduce the risk of CV events.…”

Section: Introductionmentioning

confidence: 99%

Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review

LeBras

Barry

2017

CJHP

View full text Add to dashboard Cite

RÉSUMÉContexte : La grippe est une infection courante des voies respiratoires qui peut causer des complications, notamment des événements cardiovasculaires. On a montré que la grippe double les risques d'infarctus du myocarde. De plus, les patients atteints d'une maladie cardiovasculaire sont les plus menacés. La vaccination contre la grippe a été associée à une réduction des cas d'infarctus du myocarde, de maladie cérébrovasculaire et de décès.Objectif : Évaluer les données probantes montrant que la vaccination contre la grippe permet de réduire le nombre d'événements cardiovasculaires chez les patients déjà atteints d'une maladie cardiovasculaire. Extraction et synthèse des données : Dix études répondaient aux critères de recherche (trois essais cliniques non aléatoires, cinq essais cliniques à répartition aléatoire et deux méta-analyses). Les essais cliniques non aléa-toires et les essais cliniques à répartition aléatoire présentaient des résultats variables en ce qui touche aux décès d'origine cardiovasculaire et aux événements cardiovasculaires indésirables. Les deux méta-analyses, qui avaient en commun quatre essais cliniques à répartition aléatoire concernant des patients atteints d'une maladie cardiovasculaire, montraient que le vaccin contre la grippe permettait de réduire le nombre de décès d'origine cardiovasculaire d'environ 50 % comparativement au groupe témoin. La vaccination a aussi réduit le nombre d'événements cardiovasculaires graves d'environ 43 %; le pourcentage était plus important (54 %) dans le sous-groupe de patients ayant récemment (à l'intérieur d'un an) souffert d'un syndrome coronarien aigu. Cependant, ces résultats sont potentiellement faussés par la petite taille des échantillons, les faibles taux d'événements et la variabilité avec laquelle on signale les résultats. Il y avait aussi une forte hétérogénéité clinique entre les études, ce qui pourrait ne pas être représentatif de la pratique actuelle. ABSTRACTBackground: Influenza is a common respiratory infection that may cause complications, including cardiovascular events. Influenza illness has been shown to double the risk of myocardial infarction, with the highest risk among patients with established cardiovascular disease. Vaccination against influenza has been associated with reductions in myocardial infarction, cerebrovascular disease, and death.

show abstract

Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older

Cited by 84 publications

References 27 publications

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review

Contact Info

Product

Resources

About